Cargando…
Prolonged Treatment with DNMT Inhibitors Induces Distinct Effects in Promoters and Gene-Bodies
Treatment with the demethylating drugs 5-azacytidine (AZA) and decitabine (DAC) is now recognised as an effective therapy for patients with Myelodysplastic Syndromes (MDS), a range of disorders arising in clones of hematopoietic progenitor cells. A variety of cell models have been used to study the...
Autores principales: | Wong, Yan-Fung, Jakt, Lars Martin, Nishikawa, Shin-Ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735498/ https://www.ncbi.nlm.nih.gov/pubmed/23940695 http://dx.doi.org/10.1371/journal.pone.0071099 |
Ejemplares similares
-
Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia
por: Wong, Kah Keng, et al.
Publicado: (2019) -
Arhgef15 Promotes Retinal Angiogenesis by Mediating VEGF-Induced Cdc42 Activation and Potentiating RhoJ Inactivation in Endothelial Cells
por: Kusuhara, Sentaro, et al.
Publicado: (2012) -
Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn
por: Kobayashi, K, et al.
Publicado: (2013) -
The de novo methylation activity of Dnmt3a is distinctly different than that of Dnmt1
por: Hsieh, Chih-Lin
Publicado: (2005) -
DNMT3L Modulates Significant and Distinct Flanking Sequence Preference for DNA Methylation by DNMT3A and DNMT3B In Vivo
por: Wienholz, Bethany L., et al.
Publicado: (2010)